PIPELINE
Global Leader of Cancer Treatments
PIPELINE
ATB-301
Product outline
ATB-301 is a new anti-cancer drug in combination with TGF- β2 Targeting Antisense Oligonucleotide (ASO), which selectively inhibits TGF-β, and IL-2.
Features
- Designed based on the correlation between TGF-β overexpression and tumor progression.
- Inhibits TGF-β2 expression by complementary binding to mRNA.
-
Problem
- Immuno-oncology drugs are effective, but there is
a large difference in the response rate by cancer types- TGF-β has been found to be the main cause of
resistance to immuno-oncology drugs. -
Solution
- Improving the response rate in various cancer types
by combination therapy- Increasing treatment efficacy by using the substance
which inhibits TGF-β
Development Timeline
-
Completion of in-vitro
efficacy test- - Confirmation of anti-cancer synergistic effect
-
Completion of in-vivo
efficacy test- Charles River,
Chungbuk National Univ. - - Confirmation of anti-cancer synergistic effect
- Charles River,
-
Patent granted
- Korean IP Office
- - Patent Granted: Anti-cancer Composition Comprising TASO and IL-2
-
P1 Clinical trial
- MFDS
- Phase 1 clinical trial for solid tumor in progress
-
Expected P2
Clinical trial- MFDS
- Expect phase 2 clinical trial in solid tumor
Presentations & Publications
| Journal name | Title | Date | Data |
|---|---|---|---|
| An American Society of Clinical Oncology Journal (ASCO) 2021 |
Combination therapy of anti-sense oligonucleotide targeting TGF-beta2 (TASO) and IL-2 (Proleukin) has anti-cancer effect in solid cancer | 2021 | |
| CYTOTHERAPY 2021 |
Blockade of transforming growth factor b2 by antisense oligonucleotide improves immunotherapeutic potential of IL-2 against melanoma in a humanized mouse model | 2021.06 | |
| Cancer Immunol, Immunotherpy |
Targeting transforming growth factor‑β2 by antisense oligodeoxynucleotide accelerates T cell‑mediated tumor rejection in a humanized mouse model of triple‑negative breast cancer | 2022 |